Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 4/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.48 |
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560770 | 0.96 | PTGER2 (0.51) | PTGER2TAS2R14ALOX5KEAP1NFE2L2 | |
| SCHEMBL3555271 | 0.89 | ALOX5 (0.59) | TAS2R14ALOX5PTGESKEAP1NFE2L2 | |
| SCHEMBL3568000 | 0.88 | ALOX5 (0.50) | TAS2R14ALOX5PTGESKEAP1NFE2L2 | |
| SCHEMBL3554109 | 0.88 | ALOX5 (0.50) | TAS2R14ALOX5PTGESSMN1; SMN2 | |
| SCHEMBL3563438 | 0.88 | ALOX5 (0.49) | TAS2R14ALOX5PTGESSMN1; SMN2 | |
| SCHEMBL3555258 | 0.86 | SLC16A3 (0.53) | ALOX5PTGESKEAP1NFE2L2 | |
| SCHEMBL3554237 | 0.86 | TAS2R14 (0.57) | TAS2R14ALOX5PTGESKEAP1L3MBTL1 | |
| SCHEMBL3562118 | 0.86 | ALDH1A1 (0.44) | PTGER2TAS2R14ALOX5PTGESSMN1; SMN2 | |
| SCHEMBL3558559 | 0.85 | ALOX5 (0.47) | PTGER2ALOX5PTGESPTGER4 | |
| SCHEMBL3554230 | 0.85 | ALOX5 (0.60) | TAS2R14ALOX5PTGESKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | PTGER2 405/4885TAS2R14 3203/4885ALOX5 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.